The Science of Therapeutic Peptides · Volume VIII

Longevity, Senescence & Organ-Specific Bioregulators

Senescence, bioregulators, and organ-specific longevity peptides.

24 chapters

1. VIII.1AdipotideA postcode, a warhead, and the drug that starved fat of its blood supply→
2. VIII.2B7-33The single-chain relaxin that kept the antifibrotic signal and dropped the rest→
3. VIII.3BronchogenFour residues, two spellings, and a lung that has not been studied since 2017→
4. VIII.4CardiogenA four-residue peptide assigned to the heart, and what happens when a compound’s name belongs to somebody else→
5. VIII.5CartalaxA three-letter peptide, a Soviet military laboratory, and the question of what a bioregulator is→
6. VIII.6ChonlutenGlu-Asp-Gly — three residues assigned to the bronchi, a twin that steals its headlines, and a literature thin enough that the trade name has one PubMed hit→
7. VIII.7EpithalonA tetrapeptide, the extract it was inferred from, the family it belongs to, and a mechanism that runs in both directions→
8. VIII.8FOXO4-DRIa peptide built backwards, to kill the cells that will not die→
9. VIII.9GlutathioneThe most abundant antioxidant in the human body, and the century-long argument about whether swallowing it does anything→
10. VIII.10HumaninThe message from the ruins — a peptide found in the one part of an Alzheimer’s brain that had not died→
11. VIII.11Khavinson CytomaxesNatural organ peptide complexes, six registered medicines, and the retail names PubMed barely indexes→
12. VIII.12LivagenLys-Glu-Asp-Ala — a four-residue instruction said to unpack old chromatin, and the closed literature that is all the evidence there is→
13. VIII.13Longevity Series IndexA map of the split stack — not a deep combination monograph→
14. VIII.14MOTS-cThe message in the machine — a peptide the mitochondrion writes, and what a decade of evidence does and does not establish about it→
15. VIII.15NAD+The coenzyme that became a commodity→
16. VIII.16OvagenGlu-Asp-Leu — a three-letter peptide sold under a name that sounds like ovaries, catalogued for the liver, and studied mostly as a kidney protectant→
17. VIII.17PancragenLys-Glu-Asp-Trp — four residues assigned to the pancreas, a DNA-test namesake that is not a peptide, and one of the denser files in the Khavinson cytogen line→
18. VIII.18PinealonA three-residue peptide read out of a cattle-brain extract, a mechanism that runs through the nucleus, and an evidence base that has never left one laboratory→
19. VIII.19ProstamaxLys‑Glu‑Asp‑Pro — a four-residue peptide with a market, a patent, and almost no literature→
20. VIII.20SS-31The peptide that found its target after it reached the clinic→
21. VIII.21TestagenLys-Glu-Asp-Gly — four residues assigned to the testis, a market spelling that collides with testosterone, and a literature thin enough to read end to end→
22. VIII.22VesiluteGlu-Asp — two amino acids, a bladder assignment, and a literature thin enough to see through→
23. VIII.23VesugenLys-Glu-Asp — a three-residue vascular bioregulator, a second life in Alzheimer models, and a literature that almost never leaves one research network→
24. VIII.24VilonLys-Glu — the shortest bioactive word in the Khavinson catalogue, a stated null on pericentromeric chromatin, and the closed literature that is almost all the evidence there is→